{"id":"W4394624476","doi":"10.1016/j.oret.2024.03.014","title":"Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab","year":2024,"lang":"en","type":"article","venue":"Ophthalmology Retina","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Advancing Translational Sciences; National Eye Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; U.S. National Library of Medicine; National Institute on Aging; National Institutes of Health; Janssen Research and Development; U.S. Department of Veterans Affairs","keywords":"Medicine; Ranibizumab; Aflibercept; Hazard ratio; Bevacizumab; Incidence (geometry); Internal medicine; Cumulative incidence; Ophthalmology; Surgery; Confidence interval; Cohort","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001819959,0.0002482481,0.0009284694,0.0009774268,0.0002394171,0.0007968955,0.0003384599,0.0006035675,0.001143764],"category_scores_gemma":[0.006619154,0.0003356042,0.003154889,0.001572498,0.0001730037,0.0004262205,0.000350399,0.0005898249,0.00008029447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004770062,"about_ca_system_score_gemma":0.0004599522,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007386242,"about_ca_topic_score_gemma":0.006724974,"domain_scores_codex":[0.9974818,0.0007192045,0.0003390845,0.0008666828,0.00037853,0.0002148059],"domain_scores_gemma":[0.9968618,0.0007098995,0.001747521,0.0002893182,0.0002054069,0.0001860625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002462374,0.00006652546,0.9869094,0.0001529881,0.005067322,0.00008201404,0.00003283722,0.0002087698,0.0002994984,0.00006081905,0.0002098949,0.004447494],"study_design_scores_gemma":[0.0004900129,0.0004358702,0.9929742,0.00005786505,0.00427131,0.0003144139,0.00006717645,0.0006024961,0.0001429577,0.0001159092,0.0005124802,0.00001533469],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883553,0.008408217,0.0004485472,0.0001388337,0.00004314107,0.00003660539,0.001734108,0.000008953477,0.0008264496],"genre_scores_gemma":[0.9981013,0.0006926146,0.0001540045,0.00007181871,0.00002751739,0.00002034879,0.0008345848,0.000002118571,0.00009567908],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007386242,"threshold_uncertainty_score":0.01468647,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005561132180104783,"score_gpt":0.2464766331168076,"score_spread":0.2409155009367029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}